Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Drug Resistance

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 21 articles:
HTML format
Text format



Single Articles


    March 2019
  1. NUNN AJ, Phillips PPJ, Meredith SK, Chiang CY, et al
    A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019 Mar 13. doi: 10.1056/NEJMoa1811867.
    PubMed     Text format     Abstract available


  2. CHURCHYARD GJ
    A Short Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019 Mar 13. doi: 10.1056/NEJMe1902904.
    PubMed     Text format    


    February 2019
  3. MCKINNELL JA, Dwyer JP, Talbot GH, Connolly LE, et al
    Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.
    N Engl J Med. 2019;380:791-793.
    PubMed     Text format    


  4. WAGENLEHNER FME, Cloutier DJ, Komirenko AS, Cebrik DS, et al
    Once-Daily Plazomicin for Complicated Urinary Tract Infections.
    N Engl J Med. 2019;380:729-740.
    PubMed     Text format     Abstract available


  5. O'RIORDAN W, Green S, Overcash JS, Puljiz I, et al
    Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
    N Engl J Med. 2019;380:528-538.
    PubMed     Text format     Abstract available


    November 2018
  6. BLANK S, Daskalakis DC
    Neisseria gonorrhoeae - Rising Infection Rates, Dwindling Treatment Options.
    N Engl J Med. 2018;379:1795-1797.
    PubMed     Text format    


    October 2018
  7. ANDREWS JR, Qamar FN, Charles RC, Ryan ET, et al
    Extensively Drug-Resistant Typhoid - Are Conjugate Vaccines Arriving Just in Time?
    N Engl J Med. 2018;379:1493-1495.
    PubMed     Text format    


    September 2018

  8. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.
    N Engl J Med. 2018 Sep 26. doi: 10.1056/NEJMoa1800474.
    PubMed     Text format     Abstract available


    August 2018
  9. COLANGELI R, Jedrey H, Kim S, Connell R, et al
    Bacterial Factors That Predict Relapse after Tuberculosis Therapy.
    N Engl J Med. 2018;379:823-833.
    PubMed     Text format     Abstract available


  10. EMU B, Fessel J, Schrader S, Kumar P, et al
    Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
    N Engl J Med. 2018;379:645-654.
    PubMed     Text format     Abstract available


  11. SHEIKH V, Murray JS, Sherwat A
    Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty.
    N Engl J Med. 2018;379:605-607.
    PubMed     Text format    


    April 2018
  12. KEENAN JD, Bailey RL, West SK, Arzika AM, et al
    Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa.
    N Engl J Med. 2018;378:1583-1592.
    PubMed     Text format     Abstract available


    March 2018
  13. GOTTLIEB GS, Raugi DN, Smith RA
    HIV Drug Resistance.
    N Engl J Med. 2018;378:874-5.
    PubMed     Text format    


  14. BERTAGNOLIO S, Jordan MR, Doherty M
    HIV Drug Resistance.
    N Engl J Med. 2018;378:874.
    PubMed     Text format    


  15. INZAULE SC, Rinke de Wit TF, Hamers RL
    HIV Drug Resistance.
    N Engl J Med. 2018;378:873-4.
    PubMed     Text format    



  16. HIV Drug Resistance.
    N Engl J Med. 2018;378:873-875.
    PubMed     Text format    


    October 2017
  17. BEYRER C, Pozniak A
    HIV Drug Resistance - An Emerging Threat to Epidemic Control.
    N Engl J Med. 2017;377:1605-1607.
    PubMed     Text format    


    September 2017
  18. MANNING BD
    Game of TOR - The Target of Rapamycin Rules Four Kingdoms.
    N Engl J Med. 2017;377:1297-9.
    PubMed     Text format    


  19. XIE YL, Chakravorty S, Armstrong DT, Hall SL, et al
    Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.
    N Engl J Med. 2017;377:1043-1054.
    PubMed     Text format     Abstract available


    June 2017
  20. RUBIN EJ
    Reviving a Drug for Tuberculosis?
    N Engl J Med. 2017;376:2292-2294.
    PubMed     Text format    


  21. BOURLIERE M, Gordon SC, Flamm SL, Cooper CL, et al
    Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
    N Engl J Med. 2017;376:2134-2146.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: